

**UNITED STATES DISTRICT COURT  
EASTERN DISTRICT OF MISSOURI  
EASTERN DIVISION**

<b>CARLA BEEN,</b>	)	
<i>individually and on behalf of</i>	)	
<i>all others similarly situated,</i>	)	
	)	
<b>Plaintiff,</b>	)	
	)	
<b>v.</b>	)	<b>Case No. 4:22CV964 HEA</b>
	)	
<b>CVS HEALTH CORPORATION,</b>	)	
<b>et al.,</b>	)	
	)	
<b>Defendants.</b>	)	

**OPINION, MEMORANDUM AND ORDER**

Plaintiff has filed a Motion to Remand Case to State Court [Doc. No. 7]. Defendant CVS Pharmacy, Inc., filed a response in opposition. The motion has been fully briefed. For the reasons set forth below, Plaintiff’s Motion will be denied.

**Background**

Plaintiff Carla Been filed this putative class action proceeding against Defendants in the Circuit Court of St. Louis County, Missouri, alleging breach of warranty, breach of implied contract, unjust enrichment, and violations of the Missouri Merchandising Practices Act (“MMPA”). Plaintiff asserts that Defendants sold over-the-counter “CVS Health” flu and cough medicine falsely

advertised as “Non-Drowsy” (the “Products”), despite containing dextromethorphan hydrobromide (“DXM”), a substance scientifically proven to cause drowsiness.

Plaintiff seeks compensatory damages, restitution, attorney’s fees, rescission, and “such further relief as the Court deems just, including injunctive relief,” and “all profits, benefits, and other compensation obtained by Defendants through [the] inequitable conduct,” on behalf of a putative class of similarly-situated Missouri citizens who purchased the Products over a five-year period in Missouri. Plaintiff also included the following stipulation in her Petition:

Although aggregate damages derived from a percentage of the Product will not exceed five million dollars (\$5,000,000.00), nonetheless **PLAINTIFF, ON BEHALF OF HERSELF AND THE PURPORTED CLASS, HEREBY DISCLAIMS AND/OR ABANDONS ANY AND ALL RECOVERY EXCEEDING FIVE MILLION DOLLARS (\$5,000,000.00).** Plaintiff and her counsel further stipulate as set forth in **Exhibit A**, hereto.

The attached Exhibit A further stated:

Plaintiff, Carla Been, individually through counsel, and Plaintiff’s counsel, Daniel Harvath, as counsel in this lawsuit (“Action”), hereby jointly stipulate and affirm the following:

- Plaintiffs will not recover, and completely disclaim recovery of, any combination of damages and/or attorneys’ fees related to this Action meeting or exceeding \$5,000,000.00;
- If Plaintiff, Carla Been, is replaced as named representative in this Action, Plaintiffs’ counsel stipulates and affirms and covenants that any and all potential class representatives for this Action must similarly stipulate and affirm the above limitation of recovery;

- Plaintiff and counsel intend for this Stipulation to continue to apply to, and bind, any other class members bringing any claim in this specific Action.

Defendant CVS Pharmacy, Inc. timely removed the matter to federal court, invoking this Court's diversity jurisdiction under the Class Action Fairness Act of 2005 (CAFA), 28 U.S.C. § 1332(d). Plaintiff filed the instant motion, requesting this case be remanded to the Circuit Court of St. Louis County, Missouri.

### **Legal Standard**

“The district courts of the United States ... are courts of limited jurisdiction. They possess only that power authorized by Constitution and statute[.]” *Exxon Mobil Corp. v. Allapattah Servs., Inc.*, 545 U.S. 546, 552 (2005) (internal quotations omitted). A state court action may be removed to federal court if the case falls within the original jurisdiction of the district courts. 28 U.S.C. § 1441(a). CAFA gives federal district courts original jurisdiction over class action cases in which “the class has more than 100 members, the parties are minimally diverse, and the amount in controversy exceeds \$5 million.” *Dart Cherokee Basin Operating Co., LLC v. Owens*, 574 U.S. 81, 84–85 (2014) (citing 28 U.S.C. §§ 1332(d)(2), (5)(B)). “To determine whether the matter in controversy exceeds the sum or value of \$5,000,000,” the “claims of the individual class members shall be aggregated.” § 1332(d)(6).

“[A] party seeking to remove under CAFA must establish the amount in controversy by a preponderance of the evidence...” *Bell v. Hershey Co.*, 557 F.3d 953, 958 (8th Cir. 2009). When a defendant “seeks federal-court adjudication, the defendant's amount-in-controversy allegation should be accepted when not contested by the plaintiff or questioned by the court.” *Dart Cherokee*, 574 U.S. at 87. But, if a plaintiff contests a defendant's asserted amount in controversy, “both sides submit proof and the court decides, by a preponderance of the evidence, whether the amount-in-controversy requirement has been satisfied.” *Id.* at 88. When determining the amount in controversy, the question ““is not whether the damages are greater than the requisite amount, but whether a fact finder might legally conclude that they are.”” *Kopp v. Kopp*, 280 F.3d 883, 885 (8th Cir. 2002).

Ordinarily, Federal courts “resolve all doubts about federal jurisdiction in favor of remand” and strictly construe removal statutes. *Dahl v. R.J. Reynolds Tobacco Co.*, 478 F.3d 965, 968 (8th Cir. 2007), quoting *Transit Cas. Co. v. Certain Underwriters at Lloyd's of London*, 119 F.3d 619, 625 (8th Cir. 1997). However, “no antiremoval presumption attends cases invoking CAFA,” because the purpose of the statute was to expand federal jurisdiction for certain class actions. *Dart Cherokee*, 574 U.S. at 89 (citing *Standard Fire Ins. Co. v. Knowles*, 568 U.S. 588, 595 (2013); S. Rep. No. 109–14, at 43 (2005) (CAFA's “provisions

should be read broadly, with a strong preference that interstate class actions should be heard in a federal court if properly removed by any defendant.”)).

### **Discussion**

In support of her motion to remand, Plaintiff argues that the minimum amount in controversy does not exceed the jurisdictional threshold of \$5,000,000 necessary to establish jurisdiction under CAFA.<sup>1</sup>

#### Plaintiff’s Precertification Stipulation

First, Plaintiff argues that her stipulation of damages in her Petition that disclaims any recovery exceeding \$5 million on behalf of Plaintiff and the “purported class” prevents removal pursuant to CAFA, incorrectly relying on *Rolwing v. Nestle Holdings, Inc.*, 666 F.3d 1069, 1072 (8th Cir. 2012) (holding that a damages stipulation could preclude removal under CAFA). The Supreme Court’s decision in *Standard Fire*, abrogating *Rolwing*, held that a precertification damages stipulation “can tie [a plaintiff’s own] hands, but it does not resolve the amount-in-controversy question” for purposes of determining whether CAFA jurisdiction exists. *Standard Fire*, 568 U.S. at 596. Plaintiff contends that her stipulation addresses the concerns in *Standard Fire* regarding a precertification stipulation for damages because her counsel, who singularly chooses the individual to present to

---

<sup>1</sup> Plaintiff does not dispute minimal diversity or that the putative class includes at least 100 members, nor does she seek to invoke any exception to CAFA jurisdiction.

the Court as a putative class representative, stipulates, as a condition of bringing and presenting this action, that any such representative must also stipulate to limit recoverable damages.

Plaintiff's argument to overcome *Standard Fire* and its progeny by this type of precertification stipulation has been rejected by not only this Court, but at least four other Courts in this district. *See, e.g., Brunts v. Hornell Brewing Co., Inc. et al.*, 2023 WL 355837, at \*2-3 (E.D. Mo. Jan. 23, 2023) (rejecting an identical stipulation); *Muller v. Glaxosmithkline Consumer Healthcare Holdings (US) LLC et al.*, 4:22CV670 HEA, 2022 WL 17718628, at \*2 (E.D. Mo. Dec. 15, 2022) (same); *Diesel v. Proctor & Gamble Co.*, 4:22CV892 MTS, 2022 WL 16948290, at \*2 (E.D. Mo. Nov. 15, 2022) (rejecting an identical stipulation and noting legally irrelevant if Plaintiff is replaced as class representative); *Dedloff v. Target Corp.*, 4:22CV868-JAR, at \*3 (E.D. Mo. Oct. 6, 2022) (rejecting an identical stipulation); *Muller v. Blue Diamond Growers*, No. 4:22 CV 707 RWS, 2022 WL 4119947, at \*2 (E.D. Mo. Sept. 9, 2022); and, *Fischer v. Vital Pharms., Inc.*, No. 4:22-CV-136 MTS, 2022 WL 1185153, at \*1 (E.D. Mo. Apr. 21, 2022). "The effect of the stipulation is the same, regardless of whether it is [Plaintiff] herself or her counsel – speaking on behalf of any future class representative – promising to limit recovery for the entire class. "It is still an effort to 'legally bind members of the proposed class before the class is certified,' in *direct contravention* of Supreme

Court precedent.” *Muller*, 2022 WL 4119947, at \*2 (citing *Standard Fire*, 568 U.S. at 593) (emphasis added). This Court agrees. CAFA jurisdiction is not defeated by Plaintiff’s precertification stipulation of damages because she “cannot legally bind members of the proposed class before the class is certified.” *Standard Fire*, 568 U.S. at 593.

#### Amount in Controversy Requirement

Next, Plaintiff argues that Defendant CVS Pharmacy, Inc. has not demonstrated, with specific facts or evidence, that there is at least \$5 million in controversy to meet its burden for removal purposes.

Defendant CVS Pharmacy, Inc.’s “burden of describing how the controversy exceeds \$5 million constitutes a pleading requirement, not a demand for proof.” *Hartis v. Chicago Title Ins. Co.*, 694 F.3d 935, 944-45 (8th Cir. 2012) (internal quotation omitted). “[T]he removing party’s burden is to show not only what the stakes of the litigation *could be*, but also what they *are* given the plaintiff’s actual demands...The demonstration concerns what the plaintiff is claiming (and thus the amount in controversy between the parties), not whether plaintiff is likely to win or be awarded everything [s]he seeks.” *Hartis*, 694 F.3d at 945 (citations omitted). The Eighth Circuit has specifically rejected the need for the defendant to provide a “formula or methodology for calculating the potential damages.” *Raskas v. Johnson & Johnson*, 719 F.3d 884, 888 (8th Cir. 2013), quoting *Hartis*, 694 F.3d at

945. The removing party “may introduce affidavits, declarations, or other documentation to satisfy the preponderance of the evidence standard.” *Faltermeier v. FCA US LLC*, 2016 WL 10879705, at \*2, *aff’d*, 899 F.3d 617 (8th Cir. 2018), quoting *Pretka v. Kolter City Plaza II, Inc.*, 608 F.3d 744, 755 (11th Cir. 2010) (cited with approval in *Raskas*, 719 F.3d at 888).

In its Response in opposition, Defendant CVS Pharmacy, Inc., attached a declaration of Jessica Donohue, who is the Lead Director of Store Brand for Defendant CVS Pharmacy, Inc., and is familiar with the sales data of the Products at issue here. Donohue’s declaration states, under oath, that sales data for the Products described in the Plaintiff’s Petition, was collected by Defendant CVS Pharmacy, Inc., and its personnel is responsible for data collection and maintenance. Donohue declares she reviewed the relevant sales data for the products at issue, and it totals approximately \$4 million for the relevant time period.

Donohue’s sworn declaration is sufficient evidence to assist in the determination of the amount in controversy. *See, e.g., Raskas*, 719 F.3d at 888–89 (finding affidavits of total sales figures sufficient evidence to establish CAFA’s amount in controversy); *Dammann v. Progressive Direct Ins. Co.*, 856 F.3d 580, 584 (8th Cir. 2017) (concluding evidence of the challenged product’s sales, which



included sales of parties not part of the narrowly defined class, sufficient to prove CAFA's amount in controversy).

Although the total declaration of sales do not exceed CAFA's \$5,000,000 threshold, Plaintiff seeks an award of attorney's fees, that must be included in the amount-in-controversy calculation. The MMPA states that a court may "award to the prevailing party attorney's fees, based on the amount of time reasonably expended." Mo. Rev. Stat. § 407.025.1. In *Faltermeier*, the Eighth Circuit affirmed a finding where damages might total \$3.6 million and attorneys' fee award of \$1.4 million was at least possible, so the sum of damages and attorneys' fees would exceed \$5,000,000. *Faltermeier*, 899 F.3d at 622; *See Also, Berry v. Volkswagen Group of America, Inc.*, 397 S.W.3d 425, 432-33 (Mo. 2013) (upholding award of \$6,174,640 in attorneys' fees after five years of litigation). Here the compensatory damages are estimated at \$4 million, and the Court finds attorneys' fees of at least \$1.4 million is possible because it is "more likely than not that attorneys' fees" will be large "considering the expected length of the litigation, the risk and complexity involved in prosecuting class actions, and the hourly rates charged." *Faltermeier*, 899 F.3d at 622. Therefore, when considering the total estimated sales together with Plaintiff's request for attorney's fees, the Court finds Defendant CVS Pharmacy, Inc. has carried its burden to show that CAFA's amount in controversy is met. *See, Id.*

“After the party seeking to remove has shown CAFA's jurisdictional minimum by a preponderance of the evidence, ‘remand is only appropriate if the plaintiff can establish to a legal certainty that the claim is for less than the requisite amount.’” *Dammann*, 856 F.3d at 584 (8th Cir. 2017), quoting *Bell*, 557 F.3d at 956. “Even if it is highly improbable that Plaintiffs will recover the amounts Defendants have put into controversy, this does not meet the legally impossible standard.” *Raskas*, 719 F.3d at 888. Plaintiff attempts to meet this burden by her proposed recovery, set forth in her Petition, that would be “a percentage of the price paid for the Product.” Plaintiff makes no attempt to identify the actual percentage she will seek to recover, but asserts that hypothetically, the percentage could be ten percent or lower. However, Plaintiff ignores her allegations in her Petition where she seeks to recover a full refund and disgorgement for “all profits, benefits, and other compensation obtained by Defendant through this inequitable conduct.” Plaintiff fails to show that it is legally impossible for her and the putative class to recover more than \$5,000,000.

### **Conclusion**


Defendant CVS Pharmacy, Inc. demonstrated by a “preponderance of the evidence” that the amount in controversy is met, and Plaintiff did not establish to a “legal certainty” that the claim is for less than the requisite amount. *Dammann*, 856 F.3d at 583; *Bell*, 557 F.3d at 956. “No antiremoval presumption attends cases

invoking CAFA.” *Dart Cherokee*, 574 U.S. at 89 (citation omitted); S. Rep. No. 109–14, at 43 (2005) (CAFA’s “provisions should be read broadly, with a strong preference that interstate class actions should be heard in a federal court if properly removed by any defendant.”). The Court finds subject matter jurisdiction under 28 U.S.C. § 1332(d) exists in this matter, and Plaintiff’s Motion to Remand will be denied.

Accordingly,

**IT IS HEREBY ORDERED** that Plaintiff’s Motion to Remand Case to the Circuit Court of St. Louis County [Doc. No. 7] is **DENIED**.

Dated this day 5<sup>th</sup> of May, 2023.

  
\_\_\_\_\_  
HENRY EDWARD AUTREY  
UNITED STATES DISTRICT JUDGE